## CO-CHAIRS

**Prof. Giancarlo Comi**

MS neurologist,
President European Charcot Foundation
Professor of Neurology
Director of the Institute of Experimental Neurology,
Vita-Salute San Raffaele University,
Milano

**Prof. Patrick Vermersch**

MD - Neurologist
Professor of Neurology
University of Lille
Clinique neurologique, service de neurologie D et pathologie neuro-inflammatoire
CHU Lille

## Ongoing programs

Interested in going further on Multiple Sclerosis Guidelines?

Participate in post forum activities with TMA.

We offer you the opportunity to go further on Multiple Sclerosis with our dedicated programs (part of TMA Mission Areas plans), CME accredited or not.

More information:
http://www.tmacademy.org/multiple-sclerosis-guidelines-forum-information/

OR
Flash code here

European Charcot Foundation

**WITH THE SCIENTIFIC SUPPORT OF THE EUROPEAN CHARCOT FOUNDATION (ECF)**

## Contact us


TMA Foundation - Charles Schoen - Operations Director
Tel.: +33 (0) 6 08 18 77 08
Email: charles.schoen@tmacademy.org

Grant Opportunities (including CME, Advisory Boards & Customized Grants)
William Melhuish / Yann Colardelle - Tel.: + 33 (0) 6 16 54 81 57
E-mail: william@tmacademy.org and yanncol@tmacademy.org

Organization - Dr. Christian Schoen
Tel: + 33 (0)6 85 10 60 59
Email : christian.schoen@tmacademy.org


**Registration :** www.tmacademy.org

# Final Agenda

29th November 2017

1st edition

**Baveno**
Italy

# Multiple Sclerosis Guidelines Forum

Better understand the Multiple Sclerosis Guidelines development process and its implications

GUIDELINES FORUM by TMA MULTIPLE SCLEROSIS

TMA TRANSLATIONAL MEDICINE ACADEMY

# Agenda

**Clinical practice guidelines and associated implementation strategies are essential to promote optimal, evidence-based practices in Multiple Sclerosis prevention and management. While current practice guidelines are generally in agreement, specific recommendations may differ, reflecting diverging interpretations of the available evidence or the lack of sufficient data to make evidence-based recommendations. In addition, a number of questions arise as a result of a rapidly changing clinical landscape and attempts at addressing unmet clinical needs.**

**The Guidelines Forum on Multiple Sclerosis aims to gather a multidisciplinary panel of leading academic international experts and industry representatives involved in basic and clinical research to discuss the latest evidence, ongoing research and controversial issues that have implications for clinical practice.**

## Morning Session

- 08:30 – 08:40 am: Welcome and Forum agenda
  P. Vermersch (France) and G. Comi (Italy)
- 08:40 – 09:55 am: Multiple Sclerosis Guidelines key points - 1st MS Guidelines from creation to present implementation
  - » 08:40 – 08:55 am // USA - A. Rae-Grant (USA)
  - » 08:55 - 09:10 am // Europe - X. Montalban (Spain)
  - » 09:10 – 09:25 am // Russia - A. Boyko (Russia)
  - » 9:25 – 09:40 am // Middle East - Y. Bassem (Lebanon)
  - » 09:40 – 9:55 am // Australia - T. Kalincik (Australia)

09:55 – 10:15 Break

- 10:15 - 11:00 am: Multiple Sclerosis Guidelines key points
  - » 10:15 – 10:30 am // Synthesis and key messages from Guidelines - G. Comi – co-chair (European Charcot Foundation - Italy)
  - » 10:30 – 10:45 am // Evolution of EMA evaluation methods for expensive therapies - Dr. J. Borg (Maltese Medicines Authority representative)
  - » 10:45 - 11:00 am // Pending Questions - P. Vermersch - Co-Chair (France)
- 11:00 am - 12:30 pm: A – MS Guidelines DIAGNOSIS pending questions - G. Comi – Co-chair
  - » 11:00 – 11:15 am // MS and Clinical Isolated Syndrome: J. Cohen (USA)
  - » 11:15 - 11:30 am // MS and Radiologically Isolated Syndrome: C. Lebrun-Frenay (France)
  - » 11:30 – 12:00 pm // MS and biomarkers Non-imaging biomarkers: C. Teunissen (Netherlands) ; Neurofilaments dosage: J. Kuhle (Switzerland)
  - » 12:00 – 12:30 pm // MS and imaging biomarkers MRI: N. de Stefano (Italy); OCT: S. Schippling (Switzerland); Evoked potentials: L. Leocani (Italy)

12:30 – 01:30 pm: Lunch

Speakers' biosketch
Flash code here



## Afternoon Session

- 01:30 - 02:30 pm: B - MS Guidelines THERAPY pending questions (P. Vermersch – Co-chair)
  - » 01:30 - 01:45 pm // MS Switch recommendations - M.P. Sormani (Italy)
  - » 01:45 - 02:00 pm // MS Centres' role - G. Edan (France)
  - » 02:00 - 02:15 pm // Handicap and disabilities - P. Feys (Belgium)
  - » 02:15 - 02:30 pm // MS and comorbidities - R.A. Marrie (Canada)
- 02:30 – 03:45 pm
  - » 02:30 - 02:50 pm // How are socio-economic dimensions involved in the NICE evaluation of their decisions? - P. Cooper (NICE Representative)
  - » 02:50 - 3:45 pm // Industry session (Chairmen)

03:45 – 04:00 pm Break

- 04:00 - 05:15pm: C - MS Guidelines IMPLEMENTATION pending questions (G. Comi or P.Vermersch)
  - » 04:00 – 04:15 pm // EMS platform" - L. Peeters (Belgium)
  - » 04:15 – 04:30 pm // e-MS (social networks, blogs, connected objects, ⋯) - J. Hobart (United Kingdom)
  - » 04:30 – 04:45 pm // MS and patients' real life - MS Care Unit: P. J. Lycke (Sweden)
  - » 04:45 – 05:15 pm // MS and "big data": challenges and opportunities - OFSEP: B. Brochet (France) - MSBase: T. Kalincik (Australia)
- 05:15 – 05:30 pm: Industry session (Chairmen)
- 05:30 pm – 06:00 pm: Conclusions
  - » The future of MS GF - P. Vermersch (Co-chair)
  - » From MS GF to ECF Congress - G. Comi (European Charcot Foundation – Italy)

## Why attend a Guidelines Forum®?

- The development and successful implementation of guidelines requires both communication and transparency between all stakeholders. The Guidelines Forum is a closed workshop during which meaningful discussions occur between academic faculty members covering relevant topics for industry attendees.
- A better understanding of the processes involved in guidelines development and implementation will help attendees that develop drugs, biomarkers and devices, to adapt and improve their research and development programs for the future.
- Case based discussions: the success and failure stories that inevitably accompany the release of new guidelines may be a source of inspiration for further research and development.
- Guidelines really shape clinical practice if doctors and their patients adopt them. Therefore, implementation is essential. This could also translate into earlier and more efficient development of diagnostic and therapeutic tools for patients.

At the end of the meeting, all participants will have a better understanding of the unmet needs and knowledge gaps that need to be addressed by future research and development efforts, and of the most appropriate ways of progressing to conciliate and take advantage of clinical, societal, evidence-based medicine and regulatory requirements.

### Format

**A series of short presentations and discussions with a focus on practical examples, case studies and interactivity between Faculty members.**

### Who should attend?

**Attendees include industry representatives with interest in clinical trials, product development, market access, guidelines development and implementation, patients' advocacy specialists, clinical research organizations and payers.**